--- title: Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer nct_id: NCT02918474 overall_status: RECRUITING phase: NA sponsor: M.D. Anderson Cancer Center study_type: INTERVENTIONAL primary_condition: Anatomic Stage I Breast Cancer AJCC v8 countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02918474.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02918474" ct_last_update_post_date: 2026-04-16 last_seen_at: "2026-05-12T06:05:12.792Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer **Official Title:** Decision Making Tool for Contralateral Prophylactic Mastectomy **NCT ID:** [NCT02918474](https://clinicaltrials.gov/study/NCT02918474) ## Key Facts - **Status:** RECRUITING - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 15 - **Lead Sponsor:** M.D. Anderson Cancer Center - **Collaborators:** National Cancer Institute (NCI) - **Conditions:** Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Sporadic Breast Carcinoma - **Start Date:** 2017-04-28 - **Completion Date:** 2026-09-30 - **CT.gov Last Update:** 2026-04-16 ## Brief Summary This trial studies the acceptability and how well decision making tool works in supporting decision making in contralateral prophylactic mastectomy in patients with newly diagnosed breast cancer. Decision making tool may help patients with early stage breast cancer make decisions regarding their surgical options. ## Detailed Description PRIMARY OBJECTIVES: I. An online decision support tool will be field tested that provides patients facing a decision about contralateral prophylactic breast cancer (CPM) with evidence-based information about the expected incidence of contralateral breast cancer and the life expectancy benefit of CPM. The tool will be designed for use in clinical settings and viewed jointly by the patient and physician as part of a shared decision making process around CPM. OUTLINE: Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation. ## Eligibility - **Minimum age:** 18 Years - **Sex:** FEMALE - **Healthy Volunteers:** No ``` Inclusion Criteria: * Newly diagnosed ductal breast carcinoma in situ (DCIS) or stage I-III sporadic unilateral invasive breast cancer * Able to speak read or write English Exclusion Criteria: * Patients with previous breast cancer * Prior history of bilateral prophylactic mastectomy * Known to have a germline mutation that predisposes them to an increased risk of breast cancer (e.g. BRCA1/2) and/or they are considered at high risk for contralateral breast cancer on the basis of a strong family history of cancer ``` ## Arms - **Supportive care (decision making tool)** (EXPERIMENTAL) — Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation. ## Interventions - **Decision Aid** (OTHER) — Use decision making tool - **Questionnaire Administration** (OTHER) — Ancillary studies ## Primary Outcomes - **Acceptability of the decision support tool** _(time frame: Up to 2 years)_ — Patients' rating of the acceptability of the decision support tool will be assessed using questions from the Ottawa Acceptability Measures, including the clarity, amount, and balance of the information provided by the tool. Acceptability data from patients enrolled in the field test will be reported descriptively. - **Changes in patient's knowledge of contralateral prophylactic mastectomy (CPM)** _(time frame: Baseline up to 2 years)_ — Will test for change in knowledge from before to after administration of the decision support tool with a breast cancer surgeon using paired samples t-tests. - **Reductions in decisional conflict about CPM** _(time frame: Baseline up to 2 years)_ — Will be assessed using the Decisional Conflict Scale. Will test for reduction in decisional conflict from before to after administration of the decision support tool with a breast cancer surgeon using paired samples t-tests. ## Locations (1) - M D Anderson Cancer Center, Houston, Texas, United States — _RECRUITING_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.m d anderson cancer center|houston|texas|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02918474.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02918474* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*